The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Talha Burki
Talha Burki
Traci A Turner,Evan A Stein
Traci A Turner
Kalie L Tommerdahl,Robert G Nelson,Petter Bjornstad
Kalie L Tommerdahl
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study [0.03%]
达格列净在儿童和青少年2型糖尿病患者中的疗效和安全性：一项前瞻性、多中心、随机、平行分组、III期研究
William V Tamborlane,Lori M Laffel,Naim Shehadeh et al.
William V Tamborlane et al.
Background: Since there are few treatment options for young people with type 2 diabetes, we aimed to assess the efficacy and safety of dapagliflozin as add-on therapy in children, adolescents, and young adults with type 2...
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial [0.03%]
急性冠脉综合征患者代谢危险因素与依折麦布对心血管事件影响的队列研究：奥德赛Outcome随机试验的事后分析
Petr Ostadal,Philippe Gabriel Steg,Yann Poulouin et al.
Petr Ostadal et al.
Background: Many patients with acute coronary syndrome have concurrent metabolic risk factors that affect risk of major adverse cardiovascular events (MACE). We aimed to assess the effects of the PCSK9 inhibitor alirocuma...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2022 May;10(5):330-340. DOI:10.1016/S2213-8587(22)00043-2 2022
David Kerr,David Klonoff
David Kerr
Zulfiqar A Bhutta,Zia Ul Haq,Abdul Basit
Zulfiqar A Bhutta
Caring for people with diabetes and non-communicable diseases in Ukraine: a humanitarian emergency [0.03%]
乌克兰的人道主义危机：糖尿病和其他慢性疾病患者的照护需求
Galyna Maystruk,Sigiriya Aebischer Perone,Valentyna Anufriyeva et al.
Galyna Maystruk et al.
K M Venkat Narayan,Lisa R Staimez
K M Venkat Narayan